STADA’s Acquisition of Lobsor Pharmaceuticals

Baker McKenzie advised STADA Arzneimittel AG on the deal, while Lindahl advised LobSor Holding AB.

STADA Arzneimittel AG, a leading manufacturer of high-quality pharmaceuticals, completed the acquisition of Lobsor Pharmaceuticals, a Swedish-based provider of innovative therapy used for treating late-stage Parkinson’s disease.

Stada Arzneimittel AG manufactures pharmaceuticals and produces generics (products whose patents have expired), brand-name products, and cancer therapy and other special pharmaceuticals.

Lobsor Pharmaceuticals Aktiebolag produces and distributes pharmaceutical products.

The Baker McKenzie team consisted of Peder Oxhammar (Picture), Costin Mihailescu, Edvard Henriksson, Seher Budak and Maja Uppgren.

Lindahl’s team consisted of Mikael Smedeby, Hugo Norlén, Erika Svensson, Therese Norenäs and Disa Almqvist.

Involved fees earner: Seher Budak – Baker McKenzie; Edvard Henriksson – Baker McKenzie; Costin Mihailescu – Baker McKenzie; Peder Oxhammar – Baker McKenzie; Maja Uppgren – Baker McKenzie; Disa Almqvist – Lindahl; Therese Norenäs – Lindahl; Hugo Norlén – Lindahl; Mikael Smedeby – Lindahl; Erika Svensson – Lindahl;

Law Firms: Baker McKenzie; Lindahl;

Clients: LobSor Holding AB ; STADA Arzneimittel AG;